Birinapant effectively induced shrinkage of LKB1-mutant tumors in an immune-competent mouse model while showing no effect in an immune-deficient nude mouse model, presenting a potential therapeutic strategy for lung cancer patients with mutated LKB1. The gene discussed is STK11; the disease is lung carcinoma.